Webdisclosure.com

Search

SANOFI-AVENTIS (EPA:SAN) Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria

Directive transparence : information réglementée

24/02/2024 15:51